<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3295">
  <stage>Registered</stage>
  <submitdate>8/09/2011</submitdate>
  <approvaldate>8/09/2011</approvaldate>
  <nctid>NCT01435772</nctid>
  <trial_identification>
    <studytitle>Extension Study for Patients Who Have Participated in a BMN 701 Study</studytitle>
    <scientifictitle>A Long-Term Study for Extended BMN 701 Treatment of Patients With Pompe Disease Who Have Participated in a BMN 701 Study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011-001805-28</secondaryid>
    <secondaryid>POM-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pompe Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - BMN 701

Experimental: Experimental: BMN 701 - 


Other interventions: BMN 701
GILT-tagged recombinant human GAA

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Treatment-Emergent Adverse Events</outcome>
      <timepoint>264 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Anti-BMN 701 antibody titer</outcome>
      <timepoint>264 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Anti-Insulin-like-growth-factor antibody titer</outcome>
      <timepoint>264 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mean distance walked as measured by the Six-minute Walk Test (6MWT)</outcome>
      <timepoint>264 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Have completed a prior BMN 701 clinical development study;

          -  Have provided written informed consent after the nature of the study has been
             explained prior to performance of any study-related procedures. Minors may participate
             as long as they provide written assent after the nature of the study has been
             explained to them and after their parent, or legal guardian has provided written
             informed consent, prior to the performance of any study-related procedures;

          -  Have been diagnosed with late-onset Pompe Disease, based on the entry criteria of a
             prior BMN 701 study;

          -  If sexually active, be willing to use 2 known effective methods of contraception from
             Screening until 4 months after the last dose of study-drug;

          -  If female, and not considered to be of childbearing potential, be at least 2 years
             post-menopausal, or have had tubal ligation at least 1 year prior to screening, or
             have had a total hysterectomy;

          -  If female, and of childbearing potential, have a negative pregnancy test during the
             Screening Period and at the Baseline visit, and be willing to have additional
             pregnancy tests during the study;

          -  Have the ability to comply with the protocol requirements, in the opinion of the
             Investigator.</inclusivecriteria>
    <inclusiveminage>13</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Have received any experimental or approved therapy for Pompe disease, other than BMN
             701, subsequent to completion of a BMN 701 study and prior to entry into POM-002;

          -  Have received, or are anticipated to receive, any investigational medication, other
             than BMN 701, within 30 days prior to the first dose of study-drug;

          -  Are breastfeeding at screening or planning to become pregnant (self or partner) at any
             time during the study;

          -  Have a medical condition or extenuating circumstance that, in the opinion of the
             Investigator, might compromise the patient's ability to comply with the protocol
             requirements or compromise the patient's well being or safety.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>45</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/09/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA</recruitmentstate>
    <hospital>Royal Brisbane and Women's Hospital - Herston</hospital>
    <hospital>Royal Adelaide Hospital - North Adelaide</hospital>
    <postcode>4029 - Herston</postcode>
    <postcode>5006 - North Adelaide</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Salford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>BioMarin Pharmaceutical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 2 open-label, multiple dose study of BMN 701 administered by IV infusion
      every 2 weeks (qow) to patients with late-onset Pompe disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01435772</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Monitor</name>
      <address>BioMarin Pharmaceutical</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>